Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Why It Matters

The findings provide robust randomized evidence supporting the <55 mg/dL LDL target for secondary prevention, potentially accelerating guideline adoption and influencing clinicians to intensify lipid‑lowering therapy earlier, which could translate into fewer heart attacks and strokes nationwide.

Key Takeaways

• Intensive LDL <55 mg/dL cuts events 33% vs <70 mg/dL
• 3‑year primary endpoint: 6.6% vs 9.7% (HR 0.67)
• Statin + ezetimibe preferred before PCSK9 inhibitors
• Benefit consistent across subgroups; women analysis underpowered
• Trial backs 2026 US guidelines targeting LDL <55 mg/dL

Pulse Analysis

The push for ever‑lower LDL thresholds has been gaining momentum since the IMPROVE‑IT trial demonstrated incremental benefit from adding ezetimibe to statins. The 2026 American dyslipidemia guidelines now formalize that momentum, recommending an LDL goal of less than 55 mg/dL for patients with established atherosclerotic disease. By positioning ezetimibe as the first intensification step before costly PCSK9 inhibitors, the guidelines aim to balance efficacy with health‑system affordability, a strategy echoed by clinicians who see ezetimibe as a cost‑effective bridge.

Ez‑PAVE adds a rare randomized backbone to this evolving paradigm. Conducted across 17 South Korean sites, the trial randomized over 3,000 secondary‑prevention patients to either a <55 mg/dL or <70 mg/dL LDL target, using a mix of high‑intensity statins, ezetimibe, and selective PCSK9 use. The intensive arm achieved a 33% relative risk reduction in the composite of cardiovascular death, MI, stroke, revascularization, and unstable‑angina hospitalizations. Notably, the benefit persisted across most subgroups, though the study was underpowered to confirm efficacy in women, highlighting a persistent data gap that future trials must address.

Beyond the headline numbers, Ez‑PAVE underscores practical challenges in real‑world implementation. Achieving sub‑55 mg/dL LDL often requires titrating statins upward, adding ezetimibe, and eventually introducing injectable PCSK9 agents for a third of patients—a regimen that may strain adherence and payer budgets. Nonetheless, the trial’s safety profile, with no uptick in diabetes or muscle‑related events, reassures clinicians that aggressive lipid lowering is tolerable. As the evidence base expands, payers and providers will need to refine pathways that prioritize oral therapies while reserving injectables for those who truly need them, ensuring that the promise of lower LDL translates into measurable public‑health gains.